Patent details

LUC00143 Product Name: sécukinumab

Basic Information

Publication number:
LUC00143
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP141636860
Legal Status:
Withdrawn
Application number:
LUC00143
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/14/980
Marketing Authorization Type:
Marketing Authorization Date:
19/01/2015
Marketing Authorization Status:
Claimed
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
10/01/2020
First Marketing Authorization date:
19/01/2015
Grant date:
Activation date:
Publication date:
10/01/2020
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
02/06/2029
SPC Extension Expiration:
02/06/2029
Rejection date:
Withdrawal date:
04/05/2020

Owner

From:
10/01/2020
 
 

Name:
Genentech, Inc.
Address:
1 DNA Way, South San Francisco, CA 94080-4990, United States (US)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
10/01/2020
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2020/03
Publication date:
10/02/2020
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
VRV
Bulletin edition number:
2020/07
Publication date:
12/06/2020
Description:
Section L: Applications for patents or supplementary protection certificates which have been withdrawn or are deemed to have been withdrawn (art. 32, 35.1, 39.5 of the law) Renunciation to a patent or supplementary protection certificate (Art. 72 of the law) Rejected applications for extensions for pediatric use of supplementary protections certificates
Filing date Document type Number of pages
10/01/2020 General Document 3
10/01/2020 Application Form 4
10/01/2020 Publication 1
04/05/2020 Outgoing Correspondence 1
10/01/2020 General Document 83
04/05/2020 Incoming Correspondence (Post) 1
10/01/2020 Incoming Correspondence (Post) 2
10/01/2020 General Document 9
10/01/2020 Outgoing Correspondence 1